Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplivanserin 5 mg/day for insomnia with sleep maintenance difficulties
2008-003791-22Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Insomnia comparing Eplivanserin 5 mg/day with Placebo (2 arms). Primary endpoint: Change from baseline of mean PSG wake time after sleep onset (WASO) on nights 41/42. Started Nov 2008; status: completed.
02
Drugs
eplivanserin
03
Conditions
Insomnia
Beyond the preview
Go deeper on 2008-003791-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003791-22.